Margin Pressures Will Weigh But Expanding Geographies Will Offer Relief

Key Takeaways

• Shifting demographics, regulatory burdens, and intensifying competition threaten RGA's revenue growth, margin expansion, and capital flexibility in mature markets.
  
• Technological innovation and product diversification offer growth potential, but persistent claims volatility and margin pressure may constrain sustained earnings improvement.
  
• Ongoing earnings volatility, rising claims costs, complex capital management, and competitive pressures may constrain growth and profitability if strategic execution does not address key risks.

Catalysts

Provides reinsurance and financial solutions.

• While RGA is positioned to benefit from the expanding need for life and health reinsurance due to an aging global population and the opening of new geographies with rising insurance adoption, the company faces demographic headwinds in developed markets as population growth dwindles and birth rates decline. This may lead to slower organic premium growth over time and restrict revenue upside, especially in its North American stronghold.
  
• Although RGA's ongoing investment in data analytics and underwriting technology positions it to improve margins and win exclusive business globally, accelerating technological disruption from insurtech competitors and alternative risk transfer products could compress traditional reinsurance margins, hampering earnings growth and net margin expansion in the longer term.
  
• While robust capital position and growing in-force business should support both acquisitions and capital return to shareholders-a potential boost to EPS through future buybacks-rising regulatory complexity and increased capital requirements may soak up more capital for compliance and buffer purposes. This could raise costs, limit capital deployment flexibility, and ultimately weigh on profitability.
  
• Despite continuing product innovation in longevity and critical illness products responding to medical advances and shifting risk profiles (which should increase premium volumes), RGA's dependency on legacy and block transactions exposes it to volatility in claims outcomes, as seen in recent quarters, and a risk of earnings stagnation if persistent claim variability or adverse experience emerges in core books.
  
• While insurance penetration rates and shifting risk appetites among primary insurers theoretically increase cession rates and business opportunities for RGA, intensifying competition from traditional peers and non-traditional investors is contributing to sustained price pressure and underwriting margin compression, further challenging the company's ability to consistently grow net income over the long term.

Reinsurance Group of America Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more pessimistic perspective on Reinsurance Group of America compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• The bearish analysts are assuming Reinsurance Group of America's revenue will grow by 6.3% annually over the next 3 years.
• The bearish analysts assume that profit margins will increase from 5.0% today to 7.0% in 3 years time.
• The bearish analysts expect earnings to reach $2.0 billion (and earnings per share of $31.4) by about May 2029, up from $1.2 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $2.2 billion.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 8.3x on those 2029 earnings, down from 11.6x today. This future PE is lower than the current PE for the US Insurance industry at 11.5x.
• The bearish analysts expect the number of shares outstanding to decline by 0.79% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.98%, as per the Simply Wall St company report.

Risks

• Persistent volatility in U.S. individual life claims experience, as evidenced by large swings between quarters, raises concerns about RGA's ability to consistently manage claims risk and could lead to unpredictable earnings and pressure on net margins in the long term.
  
• Increasing claims costs in the U.S. healthcare excess business, attributed to more expensive treatments and specialty drugs, may signal a broader trend of rising healthcare expenses, which could compress underwriting margins and impact profitability if repricing actions do not fully offset these costs.
  
• Heavy reliance on recognizing value of in-force business and complex capital frameworks (including regulatory and rating agency capital credits) may introduce risk if actuarial or pricing assumptions diverge from actual experience or if future regulatory changes reduce the amount of allowable capital credit, potentially constraining capital deployment and limiting earnings growth.
  
• Elevated competition for asset-intensive and longevity transactions across multiple geographies, combined with RGA's selective approach to which blocks to underwrite, could restrict new business growth and slow the expansion of revenues and premium volumes over time.
  
• The company's strategy of deploying capital into new business rather than aggressively returning capital to shareholders, along with management's acknowledgment of market frustration regarding earnings volatility, suggests ongoing execution risk in balancing growth and shareholder returns, with the potential for lower EPS growth and muted share price performance if investor concerns are not addressed.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Reinsurance Group of America is $212.0, which represents up to two standard deviations below the consensus price target of $248.44. This valuation is based on what can be assumed as the expectations of Reinsurance Group of America's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $273.0, and the most bearish reporting a price target of just $212.0.
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $28.4 billion, earnings will come to $2.0 billion, and it would be trading on a PE ratio of 8.3x, assuming you use a discount rate of 7.0%.
• Given the current share price of $208.68, the analyst price target of $212.0 is 1.6% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.